18.25
Precedente Chiudi:
$18.55
Aprire:
$18.37
Volume 24 ore:
398.11K
Relative Volume:
0.17
Capitalizzazione di mercato:
$3.37B
Reddito:
$1.03B
Utile/perdita netta:
$-297.43M
Rapporto P/E:
-11.30
EPS:
-1.615
Flusso di cassa netto:
$-261.39M
1 W Prestazione:
-9.95%
1M Prestazione:
-0.53%
6M Prestazione:
-48.08%
1 anno Prestazione:
-51.81%
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Nome
Legend Biotech Corp Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare LEGN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
LEGN
Legend Biotech Corp Adr
|
18.24 | 3.53B | 1.03B | -297.43M | -261.39M | -1.615 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.99 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.91 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
689.62 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.00 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.41 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-22 | Downgrade | TD Cowen | Buy → Hold |
| 2026-01-07 | Iniziato | Oppenheimer | Outperform |
| 2025-10-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-06-17 | Iniziato | Truist | Buy |
| 2024-05-24 | Reiterato | H.C. Wainwright | Buy |
| 2024-05-23 | Iniziato | Deutsche Bank | Buy |
| 2024-04-17 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Iniziato | Raymond James | Outperform |
| 2023-12-19 | Iniziato | Scotiabank | Sector Perform |
| 2023-11-06 | Iniziato | Goldman | Buy |
| 2023-05-25 | Iniziato | William Blair | Mkt Perform |
| 2023-05-22 | Iniziato | Daiwa Securities | Buy |
| 2023-03-29 | Iniziato | H.C. Wainwright | Buy |
| 2023-03-24 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-11-02 | Iniziato | Evercore ISI | Outperform |
| 2022-11-01 | Iniziato | Cowen | Outperform |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-03-15 | Iniziato | Barclays | Overweight |
| 2022-01-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-18 | Iniziato | BTIG Research | Buy |
| 2020-07-01 | Iniziato | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Legend Biotech Corp Adr Borsa (LEGN) Ultime notizie
Q2 EPS Estimates for Legend Biotech Lowered by HC Wainwright - MarketBeat
Braidwell LP Decreases Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
NiSource (NYSE:NI) Hits New 12-Month High – Here’s Why - Defense World
UiPath (NYSE:PATH) Price Target Cut to $13.00 by Analysts at Wells Fargo & Company - Defense World
Capital International Investors Sells 140,873 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
916,443 Shares in Bath & Body Works, Inc. $BBWI Bought by Capital International Investors - Defense World
CLEAR Secure, Inc. (NYSE:YOU) Receives Average Recommendation of “Hold” from Analysts - Defense World
Royal Bank Of Canada Lowers Legend Biotech (NASDAQ:LEGN) Price Target to $62.00 - Defense World
Legend Biotech Plans to List in HK as Early as This Yr, Raising at Least US$300M: Wire - AASTOCKS.com
RBC Capital lowers Legend Biotech stock price target on model updates - Investing.com South Africa
Legend Biotech Q4 2025 slides: CARVYKTI turns profitable, $555M sales By Investing.com - Investing.com South Africa
Raymond James reiterates Legend Biotech stock rating on strong Q4 results - Investing.com India
Truist reiterates Buy on Legend Biotech stock, $70 target on capacity - Investing.com
Jefferies reiterates Legend Biotech stock rating on Carvykti sales - Investing.com India
Jefferies reiterates Legend Biotech stock rating on Carvykti sales By Investing.com - Investing.com South Africa
Legend Biotech Q4 Earnings Call Highlights - Yahoo Finance
Legend Biotech Q4 2025 slides: CARVYKTI turns profitable, $555M sales - Investing.com India
Earnings call transcript: Legend Biotech Q4 2025 shows strong growth - Investing.com
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Legend Biotech earnings on deck as profitability looms - Investing.com South Africa
Triata Capital Ltd Purchases 54,300 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Raymond James reiterates Legend Biotech stock rating after rival approval - Investing.com
Legend Biotech (NASDAQ:LEGN) Trading Up 5.5%Here's Why - MarketBeat
Artisan Partners Limited Partnership Purchases 425,684 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Westfield Capital Management Co. LP Lowers Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Nuclear Stocks To Research – February 23rd - Defense World
Raymond James reiterates Legend Biotech stock rating on valuation gap - Investing.com South Africa
Legend Biotech (NASDAQ:LEGN) Shares Gap UpStill a Buy? - MarketBeat
Etsy (NYSE:ETSY) Stock Price Up 6.6% on Earnings Beat - Defense World
Barclays Cite Favorable Long-Term Outlook For Legend Biotech Corporation (LEGN) Despite Near-Term Expectation Revisions - Finviz
FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN) - Finviz
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Legend Biotech (NASDAQ:LEGN) Downgraded by Rothschild & Co Redburn to “Neutral” - Defense World
Legend Biotech stock rating downgraded by Rothschild Redburn on competition concerns By Investing.com - Investing.com India
Legend Biotech stock rating downgraded by Rothschild Redburn on competition concerns - Investing.com
Legend Biotech (NASDAQ:LEGN) Makes Strides in Nasdaq Composite Biotech Field - Kalkine Media
Investment Analysts’ Weekly Ratings Updates for Legend Biotech (LEGN) - Defense World
Legend Biotech (LEGN) Shakes Up Board - Finviz
Legend Biotech (NASDAQ:LEGN) Sets New 12-Month LowTime to Sell? - MarketBeat
H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)'s Carvykti Despite Sales Miss - Finviz
82,516 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Bought by Mutual of America Capital Management LLC - MarketBeat
Legend Biotech stock hits 52-week low at $18.07 By Investing.com - Investing.com South Africa
Legend Biotech stock hits 52-week low at $18.07 - Investing.com
Legend Biotech (NASDAQ:LEGN) Hits New 12-Month LowTime to Sell? - MarketBeat
Legend Biotech (LEGN) Advances Cell Therapy Innovation and Expands Oncology Pipeline - Finviz
Legend Biotech FY2025 EPS Estimate Lifted by HC Wainwright - MarketBeat
Legend Biotech (NASDAQ:LEGN) Price Target Lowered to $50.00 at HC Wainwright - Defense World
Legend Biotech (NASDAQ:LEGN) Shares Gap Down on Analyst Downgrade - Defense World
H.C. Wainwright lowers Legend Biotech stock price target on Q4 sales miss By Investing.com - Investing.com South Africa
H.C. Wainwright lowers Legend Biotech stock price target on Q4 sales miss - Investing.com India
Rakuten Investment Management Inc. Takes $7.58 Million Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Corp Adr Azioni (LEGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):